Carboplatin and Paclitaxel in Treating Older Patients With Metastatic or Recurrent Unresectable Non-Small Cell Lung Cancer
This study has been completed.
North Central Cancer Treatment Group
Information provided by:
National Cancer Institute (NCI)
First received: April 6, 2000
Last updated: February 6, 2009
Last verified: June 2006
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Estimated Study Completion Date:||No date given|
|Estimated Primary Completion Date:||No date given|
Jatoi A, Hillman S, Stella PJ, Mailliard JA, Sloan J, Vanone S, Cannon MW, Kutteh L, Kanard A, Jett JR. Daily activities: exploring their spectrum and prognostic impact in older, chemotherapy-treated lung cancer patients. Support Care Cancer. 2003 Jul;11(7):460-4. Epub 2003 Mar 12.
Jatoi A, Stella PJ, Hillman S, Mailliard JA, Vanone S, Perez EA, Cannon MW, Geyer S, Wiesenfeld M, Jett JR. Weekly carboplatin and paclitaxel in elderly non-small-cell lung cancer patients (>or=65 years of age): a phase II North Central Cancer Treatment Group study. Am J Clin Oncol. 2003 Oct;26(5):441-7.
Mailliard JA, Jatoi A, Hillman S, et al.: Weekly carboplatin and paclitaxel in elderly non-small cell lung cancer patients (?65 years of age): a phase II North Central Cancer Treatment Group study. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1530, 2002.